Merck's ERK drug had a low response rate but could be used in combinations for BRAF-mutant cancers.

Scientists at the University of Cambridge have shown in animal models that reprogramming patients’ own skin cells may be an effective way to treat MS.

Months after losing its hepatitis C collaboration with Janssen, Achillion is trying to cut costs.

While the trial linked GWP42006 to around a 40% drop in focal seizures, the placebo triggered a similarly sharp decline.

Through a new online tracker, AllTrials names sponsors who fail to report clinical trial results on time per the FDAAA Final Rule.

Kite will use the ZFN gene editing platform to create next-generation, off-the-shelf CAR-T therapies to cement its position in the cell therapy space.

With the new financing, Kallyope plans to move its pipeline programs toward the clinic and hire another 16 people.

John Davis, who headed early clinical development at Pfizer, joined Magenta Therapeutics.

Months after raising a $107 million series C, Arcus Biosciences has filed for a $100 million IPO.